Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma
- 1 December 2007
- journal article
- Published by Elsevier BV in Pathology
- Vol. 39 (6), 551-557
- https://doi.org/10.1080/00313020701684409
Abstract
Summary Aims To determine if the cyclin dependent kinase inhibitors (CDKIs) p16 and p27 show reduced expression in the progression from benign to malignant melanocytic tumours, and to correlate these findings with patient prognosis. Methods Ninety-two melanocytic tumours were assessed for immunohistochemical expression of p16 and p27. These specimens included nine compound naevi, 10 dysplastic naevi, 17 thin (1mm) melanomas, 22 thick (>1mm) melanomas, nine in-transit metastases, 13 lymph node metastases, and 12 soft tissue metastases. Clinicopathological information on the 39 patients with melanoma primaries was obtained from the Sydney Melanoma Unit database. The median follow up period was 43.3 months. Results A significant loss of expression of p16 and p27 was found with tumour progression. Positive expression of p27 was found in all compound and dysplastic naevi but only 43.6% of melanoma primaries. Expression of p27 was greater in lymph node and in-transit metastases (63.6%), but lower in soft tissue metastases (36.4%). Positive expression of nuclear p16 was evident in 73.7% of benign naevi, 28.2% of primary melanomas and 14.7% of metastatic melanomas. Neither p16 nor p27 expression was significantly correlated with overall survival, disease free survival or other clinicopathological markers. Conclusions The CDKIs p16 and p27 are associated with tumour progression in melanoma, but do not reliably predict recurrence or survival.Keywords
This publication has 35 references indexed in Scilit:
- Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship*Journal of Cutaneous Pathology, 2004
- p16(MTS-1/CDKN2/INK4a) in Cancer ProgressionExperimental Cell Research, 2001
- Regulation of the Cdk inhibitor p27 and its deregulation in cancerJournal of Cellular Physiology, 2000
- High Levels of Expression of p27KIP1 and Cyclin E in Invasive Primary Malignant MelanomasJournal of Investigative Dermatology, 1999
- Expression of p-27 (kip1) in Nevi and MelanomasThe American Journal of Dermatopathology, 1999
- p27kip1: A Multifunctional Cyclin-Dependent Kinase Inhibitor with Prognostic Significance in Human CancersThe American Journal of Pathology, 1999
- The murine gene p27Kip1 is haplo-insufficient for tumour suppressionNature, 1998
- Protein Expression of the Cell-Cycle Inhibitor p27Kip1 in Malignant Melanoma: Inverse Correlation with Disease-Free SurvivalThe American Journal of Pathology, 1998
- Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cellsOncogene, 1998
- Mice Lacking p27 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary TumorsCell, 1996